30 November 2021 - ICPerMed launched its fourth Recognition. The objective of the ICPerMed Recognition 2021 is to honour, encourage, promote and disseminate outstanding evidence-based applications in the field of personalised medicine (PM), focusing on the implementation of PM research. The deadline for proposal submission was 18 February 2022.
The Recognition was open to candidates worldwide, who have published scientific papers (paper accepted by the respective editor) and/or developed best practice strategies (training programmes or interdisciplinary/intersectoral groups of collaboration) for implementation of PM approaches between 1 November 2019 and 31 December 2020.
The winners of the ICPerMed Best Practice in Personalised Medicine Recognition 2021 are:
|Alterations in serum glutamate levels are presented as a new risk factor in Metabolic associated fatty liver Disease||Jorge Simon||Spain|
|3||ICPerMed_BPR_2021_07||A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer||Ludmilla Thomé Domingos Chinen||Brazil|
Dr. Jorge Simon (Spain), Dr. Jose Beloqui (Spain) and Dr. Ludmilla Thomé Domingos Chinen (Brazil) qualified and will be invited to the ICPerMed Workshop on Personalised Medicine which will take place in Brussels on June 21st and 22nd, where they will have the chance to present their work during a plenary session for further dissemination.
Moreover, the three winners will receive a €500 worth non-cash contribution for further dissemination.